Company Filing History:
Years Active: 2020-2024
Title: Hyeryung Park: Innovator in GPCR Heteromer Inhibitors
Introduction
Hyeryung Park is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer research through his innovative work on GPCR heteromer inhibitors. With a total of 2 patents, Park's inventions are paving the way for new therapeutic approaches in oncology.
Latest Patents
Hyeryung Park's latest patents focus on GPCR heteromer inhibitors and their applications in cancer treatment. His inventions specifically target inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers. These heteromers are associated with various cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors. The inventions provide methods for enhancing signaling downstream of CXCR4 through co-stimulation with CXCR4 agonists and GPCR agonists. Additionally, Park's patents include the use of inhibitors that target the interacting GPCR partner of the CXCR4-GPCR heteromer, which can be utilized in the diagnosis and therapy for cancer.
Career Highlights
Hyeryung Park is currently associated with GPCR Therapeutics, Inc., where he continues to advance his research and development efforts. His work is instrumental in exploring new avenues for cancer treatment, leveraging the unique properties of GPCR heteromers.
Collaborations
Park collaborates with esteemed colleagues, including DongSeung Seen and Eunhee Kim, who contribute to his research endeavors and help drive innovation in the field.
Conclusion
Hyeryung Park's contributions to the development of GPCR heteromer inhibitors represent a significant advancement in cancer research. His innovative patents and collaborative efforts are poised to make a lasting impact on therapeutic strategies for cancer treatment.